Precision medicine for cancer patients: Lessons learned and the path forward

Journal of the National Cancer Institute

Volumn 105, Issue 17, 2013, Pages 1262-1263

  Gazdar, Adi F ^a   Minna, John D ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; BIOLOGICAL MARKER; DNA TOPOISOMERASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; IMATINIB; MESSENGER RNA; MOLECULAR MARKER; SHORT HAIRPIN RNA; SMALL INTERFERING RNA;

ACUTE LYMPHOBLASTIC LEUKEMIA; BREAST CANCER; CANCER CELL CULTURE; CANCER PATIENT; CANCER THERAPY; CHRONIC MYELOID LEUKEMIA; EDITORIAL; GENE EXPRESSION; GENE MUTATION; HODGKIN DISEASE; HUMAN; HUMAN GENOME; LUNG NON SMALL CELL CANCER; MEDICINE; NONHUMAN; ONCOGENE; PHENOTYPE; PRECISION MEDICINE; PRIORITY JOURNAL; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HODGKIN DISEASE; HUMANS; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 84884487240     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt219     Document Type: Editorial

References (12)

1. Barretina J, Caponigro G, Stransky N, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483(7391):603-607.
2. Cancer Target Discovery and Development Network, Schreiber SL, Shamji SF, et al. Towards patient-based cancer therapeutics. Nat Biotechnol. 2010;28(9):904-906.
3. Wang W, Baggerly K, Knudsen S, et al. Independent validation of a model using cell line chemosensitivity to predict response to therapy. J Natl Cancer Inst. 2013;105(17):1284-1291.
4. Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer. 2006;6(10):813-823.
5. Gazdar AF, Girard L, Lockwood WW, et al. Lung cancer cell lines as tools for biomedical discovery and research. J Natl Cancer Inst. 2010;102(17):1310- 1321.
6. Gillet JP, Varma S, Gottesman MM. The clinical relevance of cancer cell lines. J Natl Cancer Inst. 2013;105(7):452-458.
7. Gazdar AF, Schiller JH. Predictive and prognostic factors for non-small cell lung cancer-potholes in the road to the promised land. J Natl Cancer Inst. 2011;103(24):1810-1811.
8. Kaiser J. Clinical medicine. Biomarker tests need closer scrutiny, IOM concludes. Science. 2012;335(6076):1554.
9. CBS News. Deception at Duke: fraud in cancer care. CBS News. February 12, 2012. http://www.cbsnews.com/8301-18560-162-57376073/deception-at-duke-fraud- in-cancer-care/. Accessed July 22, 2013.
10. Baggerly KA, Coombes KR. What information should be required to support clinical omics publications? Clin Chem. 2011;57:688-690.
11. Coombes KR, Wang J, Baggerly KA. Microarrays: retracing steps. Nat Med. 2007;13(11):1276-1277; author reply 1277-1278.
12. Institute of Medicine. Evolution of Translational Omics: Lessons Learned and the Path Forward. http://www.iom.edu/Reports/2012/Evolution-of- Translational-Omics.aspx. Accessed July 22, 2013.